VEGFA and age-related macular degeneration: Due to the burden of AMD treatment on health care systems and patients, the overall tendency is to reduce the total number of intraocular injections or improve the results of standard management in more patients [1]; besides, concerns about frequent intraocular injections may limit the administration of anti-VEGF agents in patients with AMD.